A 52-year-old woman with no significant past medical history presents with a 4-day history of cough, fever (39.2°C), pleuritic chest pain, and dyspnea. She lives in a community setting and has not been hospitalized recently. On examination: respiratory rate 24/min, SpO₂ 92% on room air, dullness to percussion and decreased breath sounds at the right base. Chest X-ray shows a right lower lobe consolidation with a small parapneumonic effusion. Blood cultures are pending. Sputum culture grows Streptococcus pneumoniae (penicillin-susceptible). What is the most appropriate antibiotic therapy?

Explanation

## Clinical Diagnosis: Community-Acquired Pneumonia (CAP) with Penicillin-Susceptible Streptococcus pneumoniae **Key Point:** This is CAP in an immunocompetent community-dwelling patient. Penicillin-susceptible S. pneumoniae is the most common bacterial CAP pathogen. Severity is moderate (SpO₂ 92%, respiratory rate 24, parapneumonic effusion). ### Severity Assessment | Feature | This Patient | |---------|---------------| | Age | 52 (not elderly) | | Comorbidities | None | | SpO₂ | 92% (mild hypoxemia) | | Systolic BP | Not stated (assume normal) | | Altered mental status | No | | **CURB-65 Score** | **1–2 (outpatient or short admission)** | **High-Yield:** CURB-65 score ≤1 = outpatient therapy; 2 = consider admission; ≥3 = admission/ICU. This patient is borderline but can be managed as inpatient with IV therapy given parapneumonic effusion. ### Treatment Algorithm for CAP ```mermaid flowchart TD A[CAP with S. pneumoniae]:::outcome --> B{Penicillin susceptibility?}:::decision B -->|Susceptible| C[Beta-lactam monotherapy]:::action B -->|Intermediate/Resistant| D[Higher-dose beta-lactam ± vancomycin]:::action C --> E[IV ceftriaxone 1-2 g daily]:::action E --> F[7 days total]:::action D --> G[IV ceftriaxone 2 g Q12H + vancomycin]:::action G --> H[7 days total]:::action ``` ### Antibiotic Dosing for CAP | Agent | Dose | Indication | |-------|------|------------| | **Ceftriaxone** (penicillin-susceptible) | **1–2 g daily** | **Preferred for CAP** | | Ceftriaxone (intermediate/resistant) | 2 g Q12H | Higher MIC | | Vancomycin | 15–20 mg/kg Q8–12H | Add if resistant | | Fluoroquinolone (levofloxacin) | 750 mg daily | Alternative monotherapy (older patients, atypical coverage) | | Amoxicillin | 500 mg TID | Outpatient CAP only (mild, no hypoxemia) | **Clinical Pearl:** Penicillin-susceptible S. pneumoniae is exquisitely sensitive to beta-lactams. Monotherapy with ceftriaxone 1–2 g daily is adequate and standard. Vancomycin is NOT needed for susceptible strains. **Warning:** Do NOT use oral amoxicillin in hospitalized CAP with moderate hypoxemia and effusion — IV therapy is required. Do NOT use fluoroquinolone monotherapy as first-line for documented S. pneumoniae (reserve for atypical pathogens or beta-lactam allergy). **Mnemonic:** **SMART CAP** = **S**evere (ICU) → add vancomycin; **M**oderate (ward) → cephalosporin ± macrolide; **A**typical symptoms → fluoroquinolone; **R**esistant organism → higher-dose beta-lactam + vancomycin; **T**reated → de-escalate based on culture. **Tip:** Duration is 7 days for CAP (shorter than HAP). Switch to oral therapy once clinically improving (afebrile, improving oxygenation, tolerating oral intake). [cite:Harrison 21e Ch 297; IDSA CAP Guidelines 2019]